As we enter the beginning of the end of the first phase of coronavirus epidemic, clinical teams both in specialist centres and primary care need to start focussing on recovery of diabetes services with immediate effect. Both, specialist teams and local primary care services will have a large numbers of patients, whose face to face appointments have been cancelled during the COVID Crisis. 

Degludec improves minor, severe & nocturnal hypoglycaemia in Type 1 diabetes: Association of British Clinical Diabetologists (ABCD) nationwide degludec audit

A Lumb¹, R Abraham², R Harper³, SC Bain⁴, R Rea¹, REJ Ryder⁵ on behalf of the ABCD nationwide degludec audit contributors

¹Oxford University Hospitals NHS Foundation Trust, Oxford

²London Medical Clinic, London

³The Ulster Hospital, Belfast

Insulin degludec improves minor, severe and nocuturnal hypoglycaemia in Type 1 diabetes: Association of British Clinical Diabetologists (ABCD) nationwide insulin degludec audit

A Lumb¹, R Abraham², R Harper³, SC Bain⁴, R Rea¹, REJ Ryder⁵, on behalf of the ABCD nationwide degludec audit contributors

¹Oxford University Hospitals NHS Trust, Oxford

²London Medical Clinic, London

³The Ulster Hospital, Belfast

ABCD is alarmed by NHS data reports that a quarter of those who sadly died from Covid-19 had diabetes.

News published by media outlets yesterday, it was reported that between 31 March and 12 May, 5,873 people with diabetes died, representing 26% of all deaths due to Covid-19. These reports will no doubt cause understandable anxiety and fear among people living with diabetes and their families, during already difficult times.  

Tags

• COVID-19

Characteristics and treatment outcomes of patients treated with empagliflozin in the Association of British Clinical Diabetologists (ABCD) Nationwide Empagliflozin Audit

Lack of risk factors predicting the development of genital mycotic infections among patients treated with dapagliflozin: the ABCD Nationwide Dapagliflozin Audit

KY Thong¹, M Yadagiri², P Tong³, D Barnes⁴, D Morris⁵, T Chowdhury⁶, LL Chuah⁷, M Cohen⁸, A Kennedy⁹, T Robinson¹⁰, SC Bain¹¹, KA Adamson¹², REJ Ryder² , ABCD Nationwide Dapagliflozin Audit contributors

¹University of Western Australia, Perth, Australia

The effect of dapagliflozin on HbA1c and weight after its addition to commonly prescribed dual combination diabetes medication regimes in people with type 2 diabetes in a real-world UK setting: the ABCD nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, A.Kennedy², T Pang³, L Balamuri⁴, T Robinson⁵, S Bain⁶, IW Gallen⁷, K Adamson⁸, REJ Ryder¹, the ABCD nationwide dapagliflozin audit contributors⁹

Effect of dapagliflozin on HbA1c and weight after its addition to various combinations of other diabetes medications: Association of British Clinical Diabetologist (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, T Pang², L.Balmuri³, T. Robinson⁴, S. Bain⁵, I.W. Gallen⁶, K A Adamson⁷ and R E J Ryder¹ on behalf of ABCD dapagliflozin audit contributors

¹Sandwell and West Birmingham NHS Trust, Birmingham, UK

The Glycaemic Response to Dapagliflozin according to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: the Association of British Clinical Diabetologists (ABCD) Nationwide Dapagliflozin Audit

K Y Thong¹, M Yadagiri², P S Gupta², P Winocour³, M Joshi⁴, J Wilding⁵, J W Stephens⁶, S C Bain⁶, A Robinson⁷, I W Gallen⁸, K A Adamson⁹, R E J Ryder², the ABCD nationwide dapagliflozin audit contributors¹⁰

HbA1c, weight,body mass index(BMI) and systolic blood pressure response to dapagliflozin : the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P S Gupta¹, A Kennedy², T Pang³, J Clark⁴, H Pathan¹, P C Johnston⁵, R Chudleigh⁶, A Robinson⁷, I W Gallen⁸, K A Adamson⁹, R E J Ryder¹, the ABCD nationwide dapagliflozin audit contributors¹⁰